Carcinoma in situ of cervix uteri
Chapter 2:Neoplasms
ICD-10 D06 is a billable code used to indicate a diagnosis of carcinoma in situ of cervix uteri.
Carcinoma in situ of the cervix uteri refers to a localized form of cervical cancer where abnormal cells are found in the lining of the cervix but have not invaded deeper tissues or spread to other parts of the body. This condition is often detected through routine Pap smears, which identify precancerous changes in cervical cells. The most common type of carcinoma in situ of the cervix is squamous cell carcinoma in situ, although adenocarcinoma in situ can also occur. Patients diagnosed with this condition typically undergo further evaluation, which may include colposcopy and biopsy to confirm the diagnosis and assess the extent of the disease. Treatment options often involve surgical procedures such as conization or hysterectomy, depending on the patient's age, desire for future fertility, and the extent of the disease. Regular surveillance is crucial for monitoring potential progression to invasive cancer, as untreated carcinoma in situ can lead to invasive cervical cancer over time.
Detailed documentation of Pap smear results, biopsy findings, and treatment plans.
Routine screening, abnormal Pap results, and follow-up after treatment.
Ensure accurate coding based on the type of carcinoma and treatment performed.
Comprehensive pathology reports detailing histological findings.
Biopsy interpretation and reporting of cervical lesions.
Pathologists must clearly indicate the diagnosis of carcinoma in situ to avoid coding errors.
Performed for diagnosis or treatment of carcinoma in situ.
Document indication for procedure and pathology results.
Gynecologists must ensure accurate coding based on findings.
Carcinoma in situ refers to abnormal cells that have not invaded surrounding tissues, while invasive cervical cancer indicates that cancer cells have spread beyond the cervix.
